{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:49:48Z","timestamp":1792097388221,"version":"4.4.0"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Science and Technology Program of Xuzhou","award":["KC25071"],"award-info":[{"award-number":["KC25071"]}]},{"name":"National Natural Science Foundation of China","award":["81672731"],"award-info":[{"award-number":["81672731"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"High-Quality Science and Technology Cultivation Program of Jiangsu Normal University","award":["JSNUGZL2026118"],"award-info":[{"award-number":["JSNUGZL2026118"]}],"id":[{"id":"https:\/\/ror.org\/051hvcm98","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03395-3","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:05:43Z","timestamp":1789016743000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cyclooxygenase-2 selective inhibitors in cancer prevention and therapy: inflammopharmacological basis and translational prospects"],"prefix":"10.1007","volume":"43","author":[{"given":"Ruijie","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1878-5902","authenticated-orcid":false,"given":"Shaohua","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"3395_CR1","doi-asserted-by":"publisher","first-page":"106428","DOI":"10.1016\/j.bioorg.2023.106428","volume":"134","author":"AA Fadaly W","year":"2023","unstructured":"Fadaly WA, Elshaier YA, Nemr MT, Abdellatif KR. Design, synthesis, modeling studies and biological evaluation of pyrazole derivatives linked to oxime and nitrate moieties as nitric oxide donor selective COX-2 and aromatase inhibitors with dual anti-inflammatory and anti-neoplastic activities. Bioorg Chem. 2023;134:106428. https:\/\/doi.org\/10.1016\/j.bioorg.2023.106428.","journal-title":"Bioorg Chem"},{"key":"3395_CR2","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.2147\/DDDT.S310820","volume":"15","author":"MA Abdelgawad","year":"2021","unstructured":"Abdelgawad MA, Musa A, Almalki AH, Alzarea SI, Mostafa EM, Hegazy MM, Mostafa-Hedeab G, Ghoneim MM, Parambi DGT, Bakr RB, Al-Muaikel NS, Alanazi AS, Alharbi M, Ahmad W, Bukhari SNA, Al-Sanea MM. Novel phenolic compounds as potential dual EGFR and COX-2 inhibitors: Design, semisynthesis, in vitro biological evaluation and in silico insights. Drug Des Devel Ther. 2021;15:2325\u201337. https:\/\/doi.org\/10.2147\/DDDT.S310820.","journal-title":"Drug Des Devel Ther"},{"key":"3395_CR3","doi-asserted-by":"publisher","first-page":"7561","DOI":"10.2147\/IJN.S218905","volume":"14","author":"NK Abo Aasy","year":"2019","unstructured":"Abo Aasy NK, Ragab D, Sallam MA, Abdelmonsif DA, Aly RG, Elkhodairy KA. A comparative study: the prospective influence of nanovectors in leveraging the chemopreventive potential of COX-2 inhibitors against skin cancer. Int J Nanomed. 2019;14:7561\u201381. https:\/\/doi.org\/10.2147\/IJN.S218905.","journal-title":"Int J Nanomed"},{"issue":"5","key":"3395_CR4","doi-asserted-by":"publisher","first-page":"e70114","DOI":"10.1111\/cbdd.70114","volume":"105","author":"N Agrawal","year":"2025","unstructured":"Agrawal N. A comprehensive review on the advancements of dual COX-2\/5-LOX inhibitors as anti-inflammatory drugs. Chem Biol Drug Des. 2025;105(5):e70114. https:\/\/doi.org\/10.1111\/cbdd.70114.","journal-title":"Chem Biol Drug Des"},{"issue":"6","key":"3395_CR5","doi-asserted-by":"publisher","first-page":"e156057","DOI":"10.1172\/jci.insight.156057","volume":"8","author":"K Balamurugan","year":"2023","unstructured":"Balamurugan K, Poria DK, Sehareen SW, Krishnamurthy S, Tang W, McKennett L, Padmanaban V, Czarra K, Ewald AJ, Ueno NT, Ambs S, Sharan S, Sterneck E. Stabilization of E-cadherin adhesions by COX-2\/GSK3\u03b2 signaling is a targetable pathway in metastatic breast cancer. JCI Insight. 2023;8(6):e156057. https:\/\/doi.org\/10.1172\/jci.insight.156057.","journal-title":"JCI Insight"},{"issue":"6","key":"3395_CR6","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2165\/00002512-200724060-00001","volume":"24","author":"SS Bansal","year":"2007","unstructured":"Bansal SS, Joshi A, Bansal AK. New dosage formulations for targeted delivery of cyclo-oxygenase-2 inhibitors: focus on use in the elderly. Drugs Aging. 2007;24(6):441\u201351. https:\/\/doi.org\/10.2165\/00002512-200724060-00001.","journal-title":"Drugs Aging"},{"issue":"11","key":"3395_CR7","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41584-023-01034-z","volume":"19","author":"W Bautista-Molano","year":"2023","unstructured":"Bautista-Molano W, Fern\u00e1ndez-\u00c1vila DG, Brance ML, \u00c1vila Pedretti MG, Burgos-Vargas R, Corbacho I, Cosentino VL, D\u00edaz Coto JF, Giraldo Ho E, Gomes Resende G, Guti\u00e9rrez LA, Guti\u00e9rrez M, Ib\u00e1\u00f1ez Vodnizza SE, J\u00e1uregui E, Ocampo V, Palleiro Rivero DR, Palominos PE, Pacheco Tena C, Quiceno GA, Saldarriaga-Rivera LM, Sommerfleck FA, Goecke Sariego A, Vera Barrezueta C, Vega Espinoza LE, Vega Hinojosa O, Citera G, Lozada C, Sampaio-Barros PD, Schneeberger E, Soriano ER. Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis. Nat Rev Rheumatol. 2023;19(11):724\u201337. https:\/\/doi.org\/10.1038\/s41584-023-01034-z.","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"3395_CR8","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1056\/NEJMoa061355","volume":"355","author":"MM Bertagnolli","year":"2006","unstructured":"Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355(9):873\u201384. https:\/\/doi.org\/10.1056\/NEJMoa061355.","journal-title":"N Engl J Med"},{"issue":"6","key":"3395_CR9","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1016\/0016-5085(93)90667-2","volume":"104","author":"I Bjarnason","year":"1993","unstructured":"Bjarnason I, Hayllar J, MacPherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology. 1993;104(6):1832\u201347. https:\/\/doi.org\/10.1016\/0016-5085(93)90667-2.","journal-title":"Gastroenterology"},{"issue":"14","key":"3395_CR10","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1158\/0008-5472.CAN-23-2627","volume":"84","author":"J Boumelha","year":"2024","unstructured":"Boumelha J, de Castro A, Bah N, Cha H, de Carn\u00e9 Tr\u00e9cesson S, Rana S, Tomaschko M, Anastasiou P, Mugarza E, Moore C, Goldstone R, East P, Litchfield K, Lee SH, Molina-Arcas M, Downward J. CRISPR-Cas9 screening identifies KRAS-induced COX2 as a driver of immunotherapy resistance in lung cancer. Cancer Res. 2024;84(14):2231\u201346. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-2627.","journal-title":"Cancer Res"},{"issue":"10","key":"3395_CR11","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1111\/jgs.16791","volume":"68","author":"PP Coll","year":"2020","unstructured":"Coll PP, Korc-Grodzicki B, Ristau BT, Shahrokni A, Koshy A, Filippova OT, Ali I. Cancer prevention and screening for older adults: Part 1. Lung, colorectal, bladder, and kidney cancer. J Am Geriatr Soc. 2020;68(10):2399\u2013406. https:\/\/doi.org\/10.1111\/jgs.16791.","journal-title":"J Am Geriatr Soc"},{"issue":"10","key":"3395_CR12","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1503\/cmaj.050456","volume":"172","author":"J Cotter","year":"2005","unstructured":"Cotter J, Wooltorton E. New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra). CMAJ. 2005;172(10):1299. https:\/\/doi.org\/10.1503\/cmaj.050456.","journal-title":"CMAJ"},{"issue":"18","key":"3395_CR13","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.2174\/0929867327999200917150939","volume":"28","author":"J Cui","year":"2021","unstructured":"Cui J, Jia J. Natural COX-2 inhibitors as promising anti-inflammatory agents: an update. Curr Med Chem. 2021;28(18):3622\u201346. https:\/\/doi.org\/10.2174\/0929867327999200917150939.","journal-title":"Curr Med Chem"},{"issue":"5","key":"3395_CR14","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S1470-2045(11)70030-4","volume":"12","author":"J Cuzick","year":"2011","unstructured":"Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, Forbes JF, Glaus A, Howell A, von Minckwitz G, Vogel V, Zwierzina H. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol. 2011;12(5):496\u2013503. https:\/\/doi.org\/10.1016\/S1470-2045(11)70030-4.","journal-title":"Lancet Oncol"},{"issue":"5","key":"3395_CR15","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S1470-2045(09)70035-X","volume":"10","author":"J Cuzick","year":"2009","unstructured":"Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C, Meyskens F, Senn HJ, Thun M. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009;10(5):501\u20137. https:\/\/doi.org\/10.1016\/S1470-2045(09)70035-X.","journal-title":"Lancet Oncol"},{"key":"3395_CR16","doi-asserted-by":"publisher","first-page":"721","DOI":"10.2147\/OTT.S148670","volume":"11","author":"P Dai","year":"2018","unstructured":"Dai P, Li J, Ma XP, Huang J, Meng JJ, Gong P. Efficacy and safety of COX-2 inhibitors for advanced non-small-cell lung cancer with chemotherapy: a meta-analysis. Onco Targets Ther. 2018;11:721\u201330. https:\/\/doi.org\/10.2147\/OTT.S148670.","journal-title":"Onco Targets Ther"},{"issue":"2","key":"3395_CR17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0223-5234(01)01197-7","volume":"36","author":"G Dannhardt","year":"2001","unstructured":"Dannhardt G, Kiefer W. Cyclooxygenase inhibitors\u2013current status and future prospects. Eur J Med Chem. 2001;36(2):109\u201326. https:\/\/doi.org\/10.1016\/S0223-5234(01)01197-7.","journal-title":"Eur J Med Chem"},{"issue":"2","key":"3395_CR18","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s10549-015-3267-9","volume":"149","author":"M de Pedro","year":"2015","unstructured":"de Pedro M, Baeza S, Escudero MT, Dierssen-Sotos T, G\u00f3mez-Acebo I, Poll\u00e1n M, Llorca J. Effect of COX-2 inhibitors and other non-steroidal inflammatory drugs on breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2015;149(2):525\u201336. https:\/\/doi.org\/10.1007\/s10549-015-3267-9.","journal-title":"Breast Cancer Res Treat"},{"key":"3395_CR19","doi-asserted-by":"publisher","first-page":"32063","DOI":"10.1038\/srep32063","volume":"6","author":"C Deng","year":"2016","unstructured":"Deng C, Li W, Fei Y, Li Y, Zhang F. Risk of malignancy in ankylosing spondylitis: a systematic review and meta-analysis. Sci Rep. 2016;6:32063. https:\/\/doi.org\/10.1038\/srep32063.","journal-title":"Sci Rep"},{"issue":"11","key":"3395_CR20","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.trecan.2022.07.002","volume":"8","author":"D Denk","year":"2022","unstructured":"Denk D, Greten FR. Inflammation: the incubator of the tumor microenvironment. Trends Cancer. 2022;8(11):901\u201314. https:\/\/doi.org\/10.1016\/j.trecan.2022.07.002.","journal-title":"Trends Cancer"},{"issue":"7471","key":"3395_CR21","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1136\/bmj.329.7471.867","volume":"329","author":"PA Dieppe","year":"2004","unstructured":"Dieppe PA, Ebrahim S, Martin RM, J\u00fcni P. Lessons from the withdrawal of rofecoxib. BMJ. 2004;329(7471):867\u20138. https:\/\/doi.org\/10.1136\/bmj.329.7471.867.","journal-title":"BMJ"},{"issue":"10","key":"3395_CR22","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1007\/s00204-019-02550-2","volume":"93","author":"HW Dong","year":"2019","unstructured":"Dong HW, Wang K, Chang XX, Jin FF, Wang Q, Jiang XF, Liu JR, Wu YH, Yang C. Beta-ionone-inhibited proliferation of breast cancer cells by inhibited COX-2 activity. Arch Toxicol. 2019;93(10):2993\u20133003. https:\/\/doi.org\/10.1007\/s00204-019-02550-2.","journal-title":"Arch Toxicol"},{"issue":"4","key":"3395_CR23","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/0016-5085(94)90246-1","volume":"107","author":"CE Eberhart","year":"1994","unstructured":"Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107(4):1183\u20138. https:\/\/doi.org\/10.1016\/0016-5085(94)90246-1.","journal-title":"Gastroenterology"},{"issue":"19","key":"3395_CR24","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1200\/JCO.2016.71.3743","volume":"35","author":"MJ Edelman","year":"2017","unstructured":"Edelman MJ, Wang X, Hodgson L, Cheney RT, Baggstrom MQ, Thomas SP, Gajra A, Bertino E, Reckamp KL, Molina J, Schiller JH, Mitchell-Richards K, Friedman PN, Ritter J, Milne G, Hahn OM, Stinchcombe TE, Vokes EE, Alliance for Clinical Trials in Oncology. Phase III randomized, placebo-controlled, double-blind trial of celecoxib in addition to standard chemotherapy for advanced non-small-cell lung cancer with cyclooxygenase-2 overexpression: CALGB 30801 (Alliance). J Clin Oncol. 2017;35(19):2184\u201392. https:\/\/doi.org\/10.1200\/JCO.2016.71.3743.","journal-title":"J Clin Oncol"},{"issue":"Pt 1","key":"3395_CR25","doi-asserted-by":"publisher","first-page":"118304","DOI":"10.1016\/j.ejmech.2025.118304","volume":"302","author":"MAZ El-Attar","year":"2026","unstructured":"El-Attar MAZ, Afifi OS, Ismail A, Kamel YN, Yassin HA, Nomeir HM, Nematalla HA, Angeli A, Labib HF, Eldehna WM, Supuran CT, Belal ASF, Elzahhar PA, Hassan NW. Click-modifiable isatin hydrazones as COX-2, VEGFR-2, and carbonic anhydrase inhibitors: A multi-target approach to cancer therapy. Eur J Med Chem. 2026;302(Pt 1):118304. https:\/\/doi.org\/10.1016\/j.ejmech.2025.118304.","journal-title":"Eur J Med Chem"},{"issue":"10","key":"3395_CR26","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1038\/jid.2014.192","volume":"134","author":"CA Elmets","year":"2014","unstructured":"Elmets CA, Ledet JJ, Athar M. Cyclooxygenases: mediators of UV-induced skin cancer and potential targets for prevention. J Invest Dermatol. 2014;134(10):2497\u2013502. https:\/\/doi.org\/10.1038\/jid.2014.192.","journal-title":"J Invest Dermatol"},{"issue":"12","key":"3395_CR27","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1159\/000535183","volume":"46","author":"X Fan","year":"2023","unstructured":"Fan X, Wang S, Pan K, Wang D, Wang R. Selective COX-2 inhibitor is beneficial in suppressing chronic postsurgical pain in esophageal cancer patients and may prolong patient survival. Oncol Res Treat. 2023;46(12):503\u201310. https:\/\/doi.org\/10.1159\/000535183.","journal-title":"Oncol Res Treat"},{"issue":"9","key":"3395_CR28","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/nrurol.2016.155","volume":"13","author":"A Fenner","year":"2016","unstructured":"Fenner A. Prostate cancer: A COX-2 far? Nat Rev Urol. 2016;13(9):496. https:\/\/doi.org\/10.1038\/nrurol.2016.155.","journal-title":"Nat Rev Urol"},{"issue":"23","key":"3395_CR29","doi-asserted-by":"publisher","first-page":"9246","DOI":"10.3390\/ijms21239246","volume":"21","author":"E Frejborg","year":"2020","unstructured":"Frejborg E, Salo T, Salem A. Role of cyclooxygenase-2 in head and neck tumorigenesis. Int J Mol Sci. 2020;21(23):9246. https:\/\/doi.org\/10.3390\/ijms21239246.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"3395_CR30","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41419-019-1600-7","volume":"10","author":"X Fu","year":"2019","unstructured":"Fu X, Zhang H, Chen Z, Yang Z, Shi D, Liu T, Chen W, Yao F, Su X, Deng W, Chen M, Yang A. TFAP2B overexpression contributes to tumor growth and progression of thyroid cancer through the COX-2 signaling pathway. Cell Death Dis. 2019;10(6):397. https:\/\/doi.org\/10.1038\/s41419-019-1600-7.","journal-title":"Cell Death Dis"},{"issue":"5","key":"3395_CR31","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1073\/pnas.1803999116","volume":"116","author":"A Gartung","year":"2019","unstructured":"Gartung A, Yang J, Sukhatme VP, Bielenberg DR, Fernandes D, Chang J, Schmidt BA, Hwang SH, Zurakowski D, Huang S, Kieran MW, Hammock BD, Panigrahy D. Suppression of chemotherapy-induced cytokine\/lipid mediator surge and ovarian cancer by a dual COX-2\/sEH inhibitor. Proc Natl Acad Sci U S A. 2019;116(5):1698\u2013703. https:\/\/doi.org\/10.1073\/pnas.1803999116.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"3395_CR32","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/1878-0261.13585","volume":"18","author":"N Giunashvili","year":"2024","unstructured":"Giunashvili N, Thomas JM, Schvarcz CA, Viana PHL, Aloss K, Bokhari SMZ, Ko\u00f3s Z, B\u00f3csi D, Major E, Balogh A, Beny\u00f3 Z, Hamar P. Enhancing therapeutic efficacy in triple-negative breast cancer and melanoma: synergistic effects of modulated electro-hyperthermia (mEHT) with NSAIDs especially COX-2 inhibition in in vivo models. Mol Oncol. 2024;18(4):1012\u201330. https:\/\/doi.org\/10.1002\/1878-0261.13585.","journal-title":"Mol Oncol"},{"issue":"1","key":"3395_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","volume":"51","author":"FR Greten","year":"2019","unstructured":"Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27\u201341. https:\/\/doi.org\/10.1016\/j.immuni.2019.06.025.","journal-title":"Immunity"},{"issue":"32","key":"3395_CR34","doi-asserted-by":"publisher","first-page":"4320","DOI":"10.1200\/JCO.2011.35.5214","volume":"29","author":"HJ Groen","year":"2011","unstructured":"Groen HJ, Sietsma H, Vincent A, Hochstenbag MM, van Putten JW, Dalesio O, Biesma B, Smit HJ, Termeer A, van den Hiltermann TJ, Schramel FM. Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study. J Clin Oncol. 2011;29(32):4320\u20136. https:\/\/doi.org\/10.1200\/JCO.2011.35.5214.","journal-title":"J Clin Oncol"},{"issue":"11","key":"3395_CR35","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/jnci\/djj206","volume":"98","author":"S Gr\u00f6sch","year":"2006","unstructured":"Gr\u00f6sch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst. 2006;98(11):736\u201347. https:\/\/doi.org\/10.1093\/jnci\/djj206.","journal-title":"J Natl Cancer Inst"},{"key":"3395_CR36","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.biopha.2018.03.066","volume":"102","author":"H Gungor","year":"2018","unstructured":"Gungor H, Ilhan N, Eroksuz H. The effectiveness of cyclooxygenase-2 inhibitors and evaluation of angiogenesis in the model of experimental colorectal cancer. Biomed Pharmacother. 2018;102:221\u20139. https:\/\/doi.org\/10.1016\/j.biopha.2018.03.066.","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"3395_CR37","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/0021-9681(85)90120-1","volume":"38","author":"T Hakulinen","year":"1985","unstructured":"Hakulinen T, Isom\u00e4ki HA, Knekt P. Multiple tumor incidence in patients with rheumatoid arthritis or allied disorders. J Chronic Dis. 1985;38(9):775\u20139. https:\/\/doi.org\/10.1016\/0021-9681(85)90120-1.","journal-title":"J Chronic Dis"},{"issue":"2","key":"3395_CR38","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s10787-009-8049-8","volume":"17","author":"RE Harris","year":"2009","unstructured":"Harris RE. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology. 2009;17(2):55\u201367. https:\/\/doi.org\/10.1007\/s10787-009-8049-8.","journal-title":"Inflammopharmacology"},{"issue":"5","key":"3395_CR39","doi-asserted-by":"publisher","first-page":"5683","DOI":"10.1002\/jcp.27411","volume":"234","author":"N Hashemi Goradel","year":"2019","unstructured":"Hashemi Goradel N, Najafi M, Salehi E, Farhood B, Mortezaee K. Cyclooxygenase-2 in cancer: A review. J Cell Physiol. 2019;234(5):5683\u201399. https:\/\/doi.org\/10.1002\/jcp.27411.","journal-title":"J Cell Physiol"},{"issue":"5","key":"3395_CR40","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1053\/bega.2001.0236","volume":"15","author":"CJ Hawkey","year":"2001","unstructured":"Hawkey CJ. COX-1 and COX-2 inhibitors. Best Pract Res Clin Gastroenterol. 2001;15(5):801\u201320. https:\/\/doi.org\/10.1053\/bega.2001.0236.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"4","key":"3395_CR41","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/codi.14556","volume":"21","author":"P He","year":"2019","unstructured":"He P, Yang C, Ye G, Xie H, Zhong W. Risks of colorectal neoplasms and cardiovascular thromboembolic events after the combined use of selective COX-2 inhibitors and aspirin with 5-year follow-up: a meta-analysis. Colorectal Dis. 2019;21(4):417\u201326. https:\/\/doi.org\/10.1111\/codi.14556.","journal-title":"Colorectal Dis"},{"issue":"4","key":"3395_CR42","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40265-025-02162-4","volume":"85","author":"G Honvo","year":"2025","unstructured":"Honvo G, Lengel\u00e9 L, Alokail M, Al-Daghri N, Reginster JY, Bruy\u00e8re O. Safety of anti-osteoarthritis medications: a systematic literature review of post-marketing surveillance studies. Drugs. 2025;85(4):505\u201355. https:\/\/doi.org\/10.1007\/s40265-025-02162-4.","journal-title":"Drugs"},{"issue":"1","key":"3395_CR43","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S2468-1253(21)00348-4","volume":"7","author":"H Hu","year":"2022","unstructured":"Hu H, Kang L, Zhang J, Wu Z, Wang H, Huang M, Lan P, Wu X, Wang C, Cao W, Hu J, Huang Y, Huang L, Wang H, Shi L, Cai Y, Shen C, Ling J, Xie X, Cai Y, He X, Dou R, Zhou J, Ma T, Zhang X, Luo S, Deng W, Ling L, Liu H, Deng Y. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7(1):38\u201348. https:\/\/doi.org\/10.1016\/S2468-1253(21)00348-4.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"3395_CR44","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12876-023-02918-w","volume":"23","author":"T Hu","year":"2023","unstructured":"Hu T, Liu CJ, Yin X, Tang W, Yin L, Bai H, Liu F, Wang D, Li Y. Selective COX-2 inhibitors do not increase gastrointestinal reactions after colorectal cancer surgery: a systematic review and meta-analysis. BMC Gastroenterol. 2023;23(1):281. https:\/\/doi.org\/10.1186\/s12876-023-02918-w.","journal-title":"BMC Gastroenterol"},{"key":"3395_CR45","doi-asserted-by":"publisher","first-page":"122954","DOI":"10.1016\/j.biomaterials.2024.122954","volume":"315","author":"R Huang","year":"2025","unstructured":"Huang R, Yu J, Zhang B, Li X, Liu H, Wang Y. Emerging COX-2 inhibitors-based nanotherapeutics for cancer diagnosis and treatment. Biomaterials. 2025;315:122954. https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122954.","journal-title":"Biomaterials"},{"issue":"Pt 2","key":"3395_CR46","doi-asserted-by":"publisher","first-page":"132721","DOI":"10.1016\/j.ijbiomac.2024.132721","volume":"277","author":"S Hussain","year":"2024","unstructured":"Hussain S, Iqbal A, Hamid S, Putra PP, Ashraf M. Identifying alkaline phosphatase inhibitory potential of cyclooxygenase-2 inhibitors: Insights from molecular docking, MD simulations, molecular expression analysis in MCF-7 breast cancer cell line and in vitro investigations. Int J Biol Macromol. 2024;277(Pt 2):132721. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.132721.","journal-title":"Int J Biol Macromol"},{"issue":"15\u201316","key":"3395_CR47","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.lfs.2011.02.008","volume":"88","author":"M Isono","year":"2011","unstructured":"Isono M, Suzuki T, Hosono K, Hayashi I, Sakagami H, Uematsu S, Akira S, DeClerck YA, Okamoto H, Majima M. Microsomal prostaglandin E synthase-1 enhances bone cancer growth and bone cancer-related pain behaviors in mice. Life Sci. 2011;88(15\u201316):693\u2013700. https:\/\/doi.org\/10.1016\/j.lfs.2011.02.008.","journal-title":"Life Sci"},{"issue":"28","key":"3395_CR48","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.3748\/wjg.v27.i28.4653","volume":"27","author":"XK Ji","year":"2021","unstructured":"Ji XK, Madhurapantula SV, He G, Wang KY, Song CH, Zhang JY, Wang KJ. Genetic variant of cyclooxygenase-2 in gastric cancer: More inflammation and susceptibility. World J Gastroenterol. 2021;27(28):4653\u201366. https:\/\/doi.org\/10.3748\/wjg.v27.i28.4653.","journal-title":"World J Gastroenterol"},{"key":"3395_CR49","doi-asserted-by":"publisher","first-page":"102609","DOI":"10.1016\/j.tranon.2025.102609","volume":"63","author":"Y Jimusi, Han","year":"2026","unstructured":"Jimusi, Han Y, Su X, Li Q, Liu S, Cheng S, Shen W, He J, Yuesitu N. L-theanine\u2019s therapeutic effects on colorectal cancer: Mechanistic insights from a 1,2-dimethylhydrazine-induced rat model. Transl Oncol. 2026;63:102609. https:\/\/doi.org\/10.1016\/j.tranon.2025.102609.","journal-title":"Transl Oncol"},{"key":"3395_CR50","doi-asserted-by":"publisher","first-page":"1099811","DOI":"10.3389\/fonc.2023.1099811","volume":"13","author":"K Jin","year":"2023","unstructured":"Jin K, Qian C, Lin J, Liu B. Cyclooxygenase-2-Prostaglandin E2 pathway: A key player in tumor-associated immune cells. Front Oncol. 2023;13:1099811. https:\/\/doi.org\/10.3389\/fonc.2023.1099811.","journal-title":"Front Oncol"},{"key":"3395_CR51","doi-asserted-by":"publisher","first-page":"108164","DOI":"10.1016\/j.bioorg.2025.108164","volume":"156","author":"L Jin","year":"2025","unstructured":"Jin L, Liao X, Yuan F, Wang Y, Liao YX, Liu B, Kou J, Li J, Huang X, Zhong X, Lim JY, Zhang J, Ren WX. COX-2-targeted fluorescent probe for ClO\u2013 monitoring in precise cancer detection. Bioorg Chem. 2025;156:108164. https:\/\/doi.org\/10.1016\/j.bioorg.2025.108164.","journal-title":"Bioorg Chem"},{"issue":"8","key":"3395_CR52","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1136\/annrheumdis-2020-217050","volume":"79","author":"Z Jin","year":"2020","unstructured":"Jin Z, Wang D, Zhang H, Liang J, Feng X, Zhao J, Sun L. Incidence trend of five common musculoskeletal disorders from 1990 to 2017 at the global, regional and national level: results from the global burden of disease study 2017. Ann Rheum Dis. 2020;79(8):1014\u201322. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217050.","journal-title":"Ann Rheum Dis"},{"issue":"19","key":"3395_CR53","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.2217\/nnm-2021-0086","volume":"16","author":"AF Khafaga","year":"2021","unstructured":"Khafaga AF, Shamma RN, Abdeen A, Barakat AM, Noreldin AE, Elzoghby AO, Sallam MA. Celecoxib repurposing in cancer therapy: molecular mechanisms and nanomedicine-based delivery technologies. Nanomed (Lond). 2021;16(19):1691\u2013712. https:\/\/doi.org\/10.2217\/nnm-2021-0086.","journal-title":"Nanomed (Lond)"},{"issue":"1","key":"3395_CR54","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10549-011-1521-3","volume":"132","author":"HS Kim","year":"2012","unstructured":"Kim HS, Moon HG, Han W, Yom CK, Kim WH, Kim JH, Noh DY. COX2 overexpression is a prognostic marker for Stage III breast cancer. Breast Cancer Res Treat. 2012;132(1):51\u20139. https:\/\/doi.org\/10.1007\/s10549-011-1521-3.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"3395_CR55","doi-asserted-by":"publisher","first-page":"e0209264","DOI":"10.1371\/journal.pone.0209264","volume":"14","author":"J Kwon","year":"2019","unstructured":"Kwon J, Kim S, Yoo H, Lee E. Nimesulide-induced hepatotoxicity: A systematic review and meta-analysis. PLoS ONE. 2019;14(1):e0209264. https:\/\/doi.org\/10.1371\/journal.pone.0209264.","journal-title":"PLoS ONE"},{"issue":"1","key":"3395_CR56","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1053\/j.gastro.2008.05.030","volume":"135","author":"L Laine","year":"2008","unstructured":"Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defense and cytoprotection: bench to bedside. Gastroenterology. 2008;135(1):41\u201360. https:\/\/doi.org\/10.1053\/j.gastro.2008.05.030.","journal-title":"Gastroenterology"},{"issue":"4","key":"3395_CR57","doi-asserted-by":"publisher","first-page":"100922","DOI":"10.1016\/j.accpm.2021.100922","volume":"40","author":"A Lemoine","year":"2021","unstructured":"Lemoine A, Witdouck A, Beloeil H, Bonnet F. PROSPECT guidelines update for evidence-based pain management after prostatectomy for cancer. Anaesth Crit Care Pain Med. 2021;40(4):100922. https:\/\/doi.org\/10.1016\/j.accpm.2021.100922.","journal-title":"Anaesth Crit Care Pain Med"},{"issue":"4","key":"3395_CR58","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1093\/rheumatology\/keu391","volume":"54","author":"C Li","year":"2015","unstructured":"Li C, Liu T, Sun W, Wu L, Zou ZY. Prevalence and risk factors of arthritis in a middle-aged and older Chinese population: the China health and retirement longitudinal study. Rheumatology (Oxford). 2015;54(4):697\u2013706. https:\/\/doi.org\/10.1093\/rheumatology\/keu391.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"3395_CR59","doi-asserted-by":"publisher","first-page":"109","DOI":"10.21873\/cgp.20564","volume":"23","author":"LI Li","year":"2026","unstructured":"Li LI, Cheng J, Guo HL, Liu QI, Wang NA, Wu CX, Sun H. Augmenter of liver regeneration enhances hepatocellular carcinoma cell growth through COX-2-associated signaling. Cancer Genomics Proteom. 2026;23(1):109\u201326. https:\/\/doi.org\/10.21873\/cgp.20564.","journal-title":"Cancer Genomics Proteom"},{"issue":"13","key":"3395_CR60","doi-asserted-by":"publisher","first-page":"e18515","DOI":"10.1111\/jcmm.18515","volume":"28","author":"Q Li","year":"2024","unstructured":"Li Q, Zhou L, Xia D, Wang J. Rheumatoid arthritis reduces the risk of colorectal cancer through immune inflammation mediation. J Cell Mol Med. 2024;28(13):e18515. https:\/\/doi.org\/10.1111\/jcmm.18515.","journal-title":"J Cell Mol Med"},{"key":"3395_CR61","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ejmech.2019.03.008","volume":"169","author":"Z Li","year":"2019","unstructured":"Li Z, Wang ZC, Li X, Abbas M, Wu SY, Ren SZ, Liu QX, Liu Y, Chen PW, Duan YT, Lv PC, Zhu HL. Design, synthesis and evaluation of novel diaryl-1,5-diazoles derivatives bearing morpholine as potent dual COX-2\/5-LOX inhibitors and antitumor agents. Eur J Med Chem. 2019;169:168\u201384. https:\/\/doi.org\/10.1016\/j.ejmech.2019.03.008.","journal-title":"Eur J Med Chem"},{"issue":"8","key":"3395_CR62","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/hed.10108","volume":"24","author":"DT Lin","year":"2002","unstructured":"Lin DT, Subbaramaiah K, Shah JP, Dannenberg AJ, Boyle JO. Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck. 2002;24(8):792\u20139. https:\/\/doi.org\/10.1002\/hed.10108.","journal-title":"Head Neck"},{"issue":"1","key":"3395_CR63","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41401-023-01158-8","volume":"45","author":"H Liu","year":"2024","unstructured":"Liu H, Deng R, Zhu CW, Han HK, Zong GF, Ren L, Cheng P, Wei ZH, Zhao Y, Yu SY, Lu Y. Rosmarinic acid in combination with ginsenoside Rg1 suppresses colon cancer metastasis via co-inhibition of COX-2 and PD1\/PD-L1 signaling axis. Acta Pharmacol Sin. 2024;45(1):193\u2013208. https:\/\/doi.org\/10.1038\/s41401-023-01158-8.","journal-title":"Acta Pharmacol Sin"},{"issue":"Pt 2","key":"3395_CR64","doi-asserted-by":"publisher","first-page":"126696","DOI":"10.1016\/j.saa.2025.126696","volume":"344","author":"J Liu","year":"2026","unstructured":"Liu J, Zhang Y, Hu J, Chen S, Xue Y, Liu W, Shen L, Wang A, Zhu Y, Xu L. A near-infrared AIE probe targeting COX-2 for imaging of cancer cells. Spectrochim Acta Mol Biomol Spectrosc. 2026;344(Pt 2):126696. https:\/\/doi.org\/10.1016\/j.saa.2025.126696.","journal-title":"Spectrochim Acta Mol Biomol Spectrosc"},{"issue":"7","key":"3395_CR65","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1097\/CM9.0000000000002514","volume":"136","author":"Y Ma","year":"2023","unstructured":"Ma Y, You W, Cao Y, He X, Wang J, Zhang Y, Li J, Li J. Chemoprevention of colorectal cancer in general population and high-risk population: a systematic review and network meta-analysis. Chin Med J (Engl). 2023;136(7):788\u201398. https:\/\/doi.org\/10.1097\/CM9.0000000000002514.","journal-title":"Chin Med J (Engl)"},{"issue":"9","key":"3395_CR66","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/13543776.2024.2373771","volume":"34","author":"M Mahboubi-Rabbani","year":"2024","unstructured":"Mahboubi-Rabbani M, Abdolghaffari AH, Ghesmati M, Amini A, Zarghi A. Selective COX-2 inhibitors as anticancer agents: a patent review (2018\u20132023). Expert Opin Ther Pat. 2024;34(9):733\u201357. https:\/\/doi.org\/10.1080\/13543776.2024.2373771.","journal-title":"Expert Opin Ther Pat"},{"issue":"13","key":"3395_CR67","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1001\/jama.2021.2454","volume":"325","author":"JA Meyerhardt","year":"2021","unstructured":"Meyerhardt JA, Shi Q, Fuchs CS, Meyer J, Niedzwiecki D, Zemla T, Kumthekar P, Guthrie KA, Couture F, Kuebler P, Bendell JC, Kumar P, Lewis D, Tan B, Bertagnolli M, Grothey A, Hochster HS, Goldberg RM, Venook A, Blanke C, O\u2019Reilly EM, Shields AF. Effect of celecoxib vs placebo added to standard adjuvant therapy on disease-free survival among patients with stage III colon cancer: the CALGB\/SWOG 80702 (Alliance) randomized clinical trial. JAMA. 2021;325(13):1277\u201386. https:\/\/doi.org\/10.1001\/jama.2021.2454.","journal-title":"JAMA"},{"key":"3395_CR68","doi-asserted-by":"publisher","first-page":"173325","DOI":"10.1016\/j.ejphar.2020.173325","volume":"882","author":"MA Mishan","year":"2020","unstructured":"Mishan MA, Khazeei Tabari MA, Zargari M, Bagheri A. MicroRNAs in the anticancer effects of celecoxib: A systematic review. Eur J Pharmacol. 2020;882:173325. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173325.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"3395_CR69","first-page":"198","volume":"46","author":"J Ml\u00edchov\u00e1","year":"2025","unstructured":"Ml\u00edchov\u00e1 J, M\u00e9sz\u00e1ros V, \u0160imandl O, Kmon\u00ed\u010dkov\u00e1 E, Kal\u00e1tov\u00e1 D, Paluch Z. Safety profile of meloxicam: analysis of adverse event reports in the Czech Republic. Neuro Endocrinol Lett. 2025;46(3):198\u2013202.","journal-title":"Neuro Endocrinol Lett"},{"issue":"Pt 1","key":"3395_CR70","doi-asserted-by":"publisher","first-page":"137599","DOI":"10.1016\/j.ijbiomac.2024.137599","volume":"283","author":"R Murugan","year":"2024","unstructured":"Murugan R, Selvam M, Haridevamuthu B, Ashok K, Chagaleti BK, Priya D, Rajagopal R, Alfarhan A, Kumaradoss KM, Arockiaraj J. 1,5- diaryl pyrazole-loaded chitosan nanoparticles as COX-2 inhibitors, mitigate neoplastic growth by regulating NF-\u03baB pathway in-vivo zebrafish model. Int J Biol Macromol. 2024;283(Pt 1):137599. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.137599.","journal-title":"Int J Biol Macromol"},{"issue":"8","key":"3395_CR71","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/cncr.32010","volume":"125","author":"GP Nagaraju","year":"2019","unstructured":"Nagaraju GP, El-Rayes BF. Cyclooxygenase-2 in gastrointestinal malignancies. Cancer. 2019;125(8):1221\u20137. https:\/\/doi.org\/10.1002\/cncr.32010.","journal-title":"Cancer"},{"issue":"1","key":"3395_CR72","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/jnci\/dju345","volume":"107","author":"K Ng","year":"2014","unstructured":"Ng K, Meyerhardt JA, Chan AT, Sato K, Chan JA, Niedzwiecki D, Saltz LB, Mayer RJ, Benson AB 3rd, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Venook AP, Ogino S, Giovannucci EL, Fuchs CS. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst. 2014;107(1):345. https:\/\/doi.org\/10.1093\/jnci\/dju345.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"3395_CR73","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1093\/annonc\/mdh185","volume":"15","author":"P Nix","year":"2004","unstructured":"Nix P, Lind M, Greenman J, Stafford N, Cawkwell L. Expression of Cox-2 protein in radioresistant laryngeal cancer. Ann Oncol. 2004;15(5):797\u2013801. https:\/\/doi.org\/10.1093\/annonc\/mdh185.","journal-title":"Ann Oncol"},{"issue":"24","key":"3395_CR74","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1200\/JCO.23.01680","volume":"42","author":"JA Nowak","year":"2024","unstructured":"Nowak JA, Twombly T, Ma C, Shi Q, Haruki K, Fujiyoshi K, V\u00e4yrynen J, Zhao M, Knight J, Mane S, Shergill A, Kumar P, Couture F, Kuebler P, Krishnamurthi S, Tan B, Philip P, O\u2019Reilly EM, Shields AF, Ogino S, Fuchs CS, Meyerhardt JA. Improved survival with adjuvant COX-2 inhibition in PIK3CA-activated stage III colon cancer: CALGB\/SWOG 80702 (Alliance). J Clin Oncol. 2024;42(24):2853\u20139. https:\/\/doi.org\/10.1200\/JCO.23.01680.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3395_CR75","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0092-8674(00)81988-1","volume":"87","author":"M Oshima","year":"1996","unstructured":"Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM. Suppression of intestinal polyposis in Apc\u25b3716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 1996;87(5):803\u20139. https:\/\/doi.org\/10.1016\/S0092-8674(00)81988-1.","journal-title":"Cell"},{"issue":"5","key":"3395_CR76","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41416-023-02552-z","volume":"130","author":"Y Ouyang","year":"2024","unstructured":"Ouyang Y, Zhong W, Xu P, Wang B, Zhang L, Yang M, Chen J, Li H, Li S, Chen X, Xu L, Ou Z, Wu D, Lin Y, Wang C, Huang J, Lin T. Tumor-associated neutrophils suppress CD8+ T cell immunity in urothelial bladder carcinoma through the COX-2\/PGE2\/IDO1 axis. Br J Cancer. 2024;130(5):880\u201391. https:\/\/doi.org\/10.1038\/s41416-023-02552-z.","journal-title":"Br J Cancer"},{"issue":"11","key":"3395_CR77","doi-asserted-by":"publisher","first-page":"8655","DOI":"10.1007\/s00520-022-07175-3","volume":"30","author":"JGP Pandy","year":"2022","unstructured":"Pandy JGP, Franco PIG, Li RK. Prophylactic strategies for hand-foot syndrome\/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials. Support Care Cancer. 2022;30(11):8655\u201366. https:\/\/doi.org\/10.1007\/s00520-022-07175-3.","journal-title":"Support Care Cancer"},{"issue":"1","key":"3395_CR78","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S0022-3565(24)34895-5","volume":"290","author":"MR Panara","year":"1999","unstructured":"Panara MR, Renda G, Sciulli MG, Santini G, Di Giamberardino M, Rotondo MT, Tacconelli S, Seta F, Patrono C, Patrignani P. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. J Pharmacol Exp Ther. 1999;290(1):276\u201380.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"3395_CR79","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s13046-018-0926-9","volume":"37","author":"Y Peng","year":"2018","unstructured":"Peng Y, Wang Y, Tang N, Sun D, Lan Y, Yu Z, Zhao X, Feng L, Zhang B, Jin L, Yu F, Ma X, Lv C. Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway. J Exp Clin Cancer Res. 2018;37(1):248. https:\/\/doi.org\/10.1186\/s13046-018-0926-9.","journal-title":"J Exp Clin Cancer Res"},{"issue":"7","key":"3395_CR80","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3390\/gels11070500","volume":"11","author":"IA Plugariu","year":"2025","unstructured":"Plugariu IA, Bercea M, Gradinaru LM. New gel approaches for the transdermal delivery of meloxicam. Gels. 2025;11(7):500. https:\/\/doi.org\/10.3390\/gels11070500.","journal-title":"Gels"},{"issue":"5","key":"3395_CR81","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1016\/S0003-4975(02)04022-5","volume":"74","author":"SS Qadri","year":"2002","unstructured":"Qadri SS, Wang JH, Redmond KC, O\u2019Donnell AF, Aherne T, Redmond HP. The role of COX-2 inhibitors in lung cancer. Ann Thorac Surg. 2002;74(5):1648\u201352. https:\/\/doi.org\/10.1016\/S0003-4975(02)04022-5.","journal-title":"Ann Thorac Surg"},{"issue":"24","key":"3395_CR82","doi-asserted-by":"publisher","first-page":"15864","DOI":"10.1021\/acsnano.4c02947","volume":"18","author":"X Qian","year":"2024","unstructured":"Qian X, Yang H, Ye Z, Gao B, Qian Z, Ding Y, Mao Z, Du Y, Wang W. Celecoxib augments paclitaxel-induced immunogenic cell death in triple-negative breast cancer. ACS Nano. 2024;18(24):15864\u201377. https:\/\/doi.org\/10.1021\/acsnano.4c02947.","journal-title":"ACS Nano"},{"issue":"1","key":"3395_CR83","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/cncr.31594","volume":"125","author":"I Ricon","year":"2019","unstructured":"Ricon I, Hanalis-Miller T, Haldar R, Jacoby R, Ben-Eliyahu S. Perioperative biobehavioral interventions to prevent cancer recurrence through combined inhibition of \u03b2-adrenergic and cyclooxygenase 2 signaling. Cancer. 2019;125(1):45\u201356. https:\/\/doi.org\/10.1002\/cncr.31594.","journal-title":"Cancer"},{"issue":"11","key":"3395_CR84","doi-asserted-by":"publisher","first-page":"6014","DOI":"10.3390\/ijms25116014","volume":"25","author":"S Rosas","year":"2024","unstructured":"Rosas S, Kwok A, Moore J, Shi L, Smith TL, Tallant EA, Kerr BA, Willey JS. Osteoarthritis as a systemic disease promoted prostate cancer in vivo and in vitro. Int J Mol Sci. 2024;25(11):6014. https:\/\/doi.org\/10.3390\/ijms25116014.","journal-title":"Int J Mol Sci"},{"key":"3395_CR85","doi-asserted-by":"publisher","first-page":"1557790","DOI":"10.3389\/fimmu.2025.1557790","volume":"16","author":"K Sakurai","year":"2025","unstructured":"Sakurai K, Chubachi S, Miyata J, Hamamoto J, Naganuma T, Shimada T, Otake S, Nakayama S, Irie H, Tsutsumi A, Kameyama N, Hegab AE, Shimoda M, Terai H, Yasuda H, Kanai Y, Arita M, Fukunaga K. Celecoxib prevents malignant progression of smoking-induced lung tumors via suppression of the COX-2\/PGE2 signaling pathway in mice. Front Immunol. 2025;16:1557790. https:\/\/doi.org\/10.3389\/fimmu.2025.1557790.","journal-title":"Front Immunol"},{"issue":"3","key":"3395_CR86","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1124\/pharmrev.123.000901","volume":"76","author":"A Santiso","year":"2024","unstructured":"Santiso A, Heinemann A, Kargl J. Prostaglandin E2 in the tumor microenvironment, a convoluted affair mediated by EP receptors 2 and 4. Pharmacol Rev. 2024;76(3):388\u2013413. https:\/\/doi.org\/10.1124\/pharmrev.123.000901.","journal-title":"Pharmacol Rev"},{"issue":"9","key":"3395_CR87","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41569-020-0366-z","volume":"17","author":"AM Schjerning","year":"2020","unstructured":"Schjerning AM, McGettigan P, Gislason G. Cardiovascular effects and safety of (non-aspirin) NSAIDs. Nat Rev Cardiol. 2020;17(9):574\u201384. https:\/\/doi.org\/10.1038\/s41569-020-0366-z.","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"3395_CR88","first-page":"220","volume":"5","author":"A Shahiwala","year":"2002","unstructured":"Shahiwala A, Misra A. Studies in topical application of niosomally entrapped Nimesulide. J Pharm Pharm Sci. 2002;5(3):220\u20135.","journal-title":"J Pharm Pharm Sci"},{"issue":"7","key":"3395_CR89","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1053\/gast.2002.33647","volume":"122","author":"G Sigthorsson","year":"2002","unstructured":"Sigthorsson G, Simpson RJ, Walley M, Anthony A, Foster R, Hotz-Behoftsitz C, Palizban A, Pombo J, Watts J, Morham SG, Bjarnason I. COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology. 2002;122(7):1913\u201323. https:\/\/doi.org\/10.1053\/gast.2002.33647.","journal-title":"Gastroenterology"},{"issue":"3","key":"3395_CR90","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1080\/1061186X.2024.2309568","volume":"32","author":"MT Singh","year":"2024","unstructured":"Singh MT, Thaggikuppe Krishnamurthy P, Magham SV. Harnessing the synergistic potential of NK1R antagonists and selective COX-2 inhibitors for simultaneous targeting of TNBC cells and cancer stem cells. J Drug Target. 2024;32(3):258\u201369. https:\/\/doi.org\/10.1080\/1061186X.2024.2309568.","journal-title":"J Drug Target"},{"issue":"3","key":"3395_CR91","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/bjh.16635","volume":"191","author":"L Smyth","year":"2020","unstructured":"Smyth L, Blunt DN, Gatov E, Nagamuthu C, Croxford R, Mozessohn L, Cheung MC. Statin and cyclooxygenase-2 inhibitors improve survival in newly diagnosed diffuse large B-cell lymphoma: a large population-based study of 4913 subjects. Br J Haematol. 2020;191(3):396\u2013404. https:\/\/doi.org\/10.1111\/bjh.16635.","journal-title":"Br J Haematol"},{"issue":"7","key":"3395_CR92","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.3390\/biom11071049","volume":"11","author":"C Sobolewski","year":"2021","unstructured":"Sobolewski C, Legrand N. Celecoxib analogues for cancer treatment: an update on OSU-03012 and 2,5-dimethyl-celecoxib. Biomolecules. 2021;11(7):1049. https:\/\/doi.org\/10.3390\/biom11071049.","journal-title":"Biomolecules"},{"issue":"1","key":"3395_CR93","doi-asserted-by":"publisher","first-page":"ITC1","DOI":"10.7326\/AITC201901010","volume":"170","author":"JA Sparks","year":"2019","unstructured":"Sparks JA. Rheumatoid arthritis. Ann Intern Med. 2019;170(1):ITC1\u201316. https:\/\/doi.org\/10.7326\/AITC201901010.","journal-title":"Ann Intern Med"},{"issue":"4","key":"3395_CR94","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/joim.13505","volume":"292","author":"CO Stiller","year":"2022","unstructured":"Stiller CO, Hjemdahl P. Lessons from 20 years with COX-2 inhibitors: Importance of dose-response considerations and fair play in comparative trials. J Intern Med. 2022;292(4):557\u201374. https:\/\/doi.org\/10.1111\/joim.13505.","journal-title":"J Intern Med"},{"issue":"1","key":"3395_CR95","doi-asserted-by":"publisher","first-page":"e70085","DOI":"10.1111\/1756-185X.70085","volume":"28","author":"ST Su","year":"2025","unstructured":"Su ST, Lee YH, Shih PC, Wei JC. Ankylosing spondylitis and cancer risk. Int J Rheum Dis. 2025;28(1):e70085. https:\/\/doi.org\/10.1111\/1756-185X.70085.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"3395_CR96","doi-asserted-by":"publisher","first-page":"E65","DOI":"10.1208\/pt060112","volume":"6","author":"H Thakkar","year":"2005","unstructured":"Thakkar H, Sharma RK, Mishra AK, Chuttani K, Murthy RR. Albumin microspheres as carriers for the antiarthritic drug celecoxib. AAPS PharmSciTech. 2005;6(1):E65\u201373. https:\/\/doi.org\/10.1208\/pt060112.","journal-title":"AAPS PharmSciTech"},{"key":"3395_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2019.01.002","volume":"448","author":"J Tian","year":"2019","unstructured":"Tian J, Guo F, Chen Y, Li Y, Yu B, Li Y. Nanoliposomal formulation encapsulating celecoxib and genistein inhibiting COX-2 pathway and Glut-1 receptors to prevent prostate cancer cell proliferation. Cancer Lett. 2019;448:1\u201310. https:\/\/doi.org\/10.1016\/j.canlet.2019.01.002.","journal-title":"Cancer Lett"},{"issue":"1","key":"3395_CR98","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13058-021-01401-2","volume":"23","author":"J Tian","year":"2021","unstructured":"Tian J, Wang V, Wang N, Khadang B, Boudreault J, Bakdounes K, Ali S, Lebrun JJ. Identification of MFGE8 and KLK5\/7 as mediators of breast tumorigenesis and resistance to COX-2 inhibition. Breast Cancer Res. 2021;23(1):23. https:\/\/doi.org\/10.1186\/s13058-021-01401-2.","journal-title":"Breast Cancer Res"},{"issue":"Pt 1","key":"3395_CR99","doi-asserted-by":"publisher","first-page":"127080","DOI":"10.1016\/j.saa.2025.127080","volume":"348","author":"AB Tosun","year":"2026","unstructured":"Tosun AB, Akturk A, Coban MB, Diken ME, Avcikurt AS, Gultekin Tosun S, Unal F. Magneto-luminescent yttrium aluminum silicate-coated Fe3O4 nanocomposites for multimodal imaging, Cancer Theranostics, and antibacterial applications. Spectrochim Acta Mol Biomol Spectrosc. 2026;348(Pt 1):127080. https:\/\/doi.org\/10.1016\/j.saa.2025.127080.","journal-title":"Spectrochim Acta Mol Biomol Spectrosc"},{"key":"3395_CR100","doi-asserted-by":"publisher","first-page":"c7086","DOI":"10.1136\/bmj.c7086","volume":"342","author":"S Trelle","year":"2011","unstructured":"Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, Egger M, J\u00fcni P. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086. https:\/\/doi.org\/10.1136\/bmj.c7086.","journal-title":"BMJ"},{"key":"3395_CR101","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1146\/annurev.med.53.082901.103952","volume":"53","author":"ME Turini","year":"2002","unstructured":"Turini ME, DuBois RN. Cyclooxygenase-2: a therapeutic target. Annu Rev Med. 2002;53:35\u201357. https:\/\/doi.org\/10.1146\/annurev.med.53.082901.103952.","journal-title":"Annu Rev Med"},{"issue":"12","key":"3395_CR102","doi-asserted-by":"publisher","first-page":"e0166601","DOI":"10.1371\/journal.pone.0166601","volume":"11","author":"N van Helmond","year":"2016","unstructured":"van Helmond N, Steegers MA, Filippini-de Moor GP, Vissers KC, Wilder-Smith OH. Hyperalgesia and persistent pain after breast cancer surgery: a prospective randomized controlled trial with perioperative COX-2 inhibition. PLoS ONE. 2016;11(12):e0166601. https:\/\/doi.org\/10.1371\/journal.pone.0166601.","journal-title":"PLoS ONE"},{"issue":"6","key":"3395_CR103","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1053\/j.gastro.2021.09.059","volume":"161","author":"D Wang","year":"2021","unstructured":"Wang D, Cabalag CS, Clemons NJ, DuBois RN. Cyclooxygenases and prostaglandins in tumor immunology and microenvironment of gastrointestinal cancer. Gastroenterology. 2021;161(6):1813\u201329. https:\/\/doi.org\/10.1053\/j.gastro.2021.09.059.","journal-title":"Gastroenterology"},{"issue":"6","key":"3395_CR104","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/onc.2009.421","volume":"29","author":"D Wang","year":"2010","unstructured":"Wang D, Dubois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene. 2010;29(6):781\u20138. https:\/\/doi.org\/10.1038\/onc.2009.421.","journal-title":"Oncogene"},{"issue":"7","key":"3395_CR105","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1158\/1055-9965.EPI-17-0573","volume":"27","author":"J Wang","year":"2018","unstructured":"Wang J, Cho NL, Zauber AG, Hsu M, Dawson D, Srivastava A, Mitchell-Richards KA, Markowitz SD, Bertagnolli MM. Chemopreventive efficacy of the cyclooxygenase-2 (Cox-2) inhibitor, celecoxib, is predicted by adenoma expression of Cox-2 and 15-PGDH. Cancer Epidemiol Biomarkers Prev. 2018;27(7):728\u201336. https:\/\/doi.org\/10.1158\/1055-9965.EPI-17-0573.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"3395_CR106","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3390\/gels11020136","volume":"11","author":"S Wang","year":"2025","unstructured":"Wang S, Li J, Ren F, Zhang J, Song W, Ren L. New dawn in the treatment of rheumatoid arthritis: advanced insight into polymer hydrogel research. Gels. 2025;11(2):136. https:\/\/doi.org\/10.3390\/gels11020136.","journal-title":"Gels"},{"key":"3395_CR107","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.ejmech.2018.09.027","volume":"158","author":"W Wang","year":"2018","unstructured":"Wang W, Zhou H, Liu L. Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review. Eur J Med Chem. 2018;158:502\u201316. https:\/\/doi.org\/10.1016\/j.ejmech.2018.09.027.","journal-title":"Eur J Med Chem"},{"issue":"5","key":"3395_CR108","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3892\/ol.2020.11993","volume":"20","author":"X Wang","year":"2020","unstructured":"Wang X, Ye X, Zhang Y, Ji F. Flurbiprofen suppresses the inflammation, proliferation, invasion and migration of colorectal cancer cells via COX2. Oncol Lett. 2020;20(5):132. https:\/\/doi.org\/10.3892\/ol.2020.11993.","journal-title":"Oncol Lett"},{"issue":"14","key":"3395_CR109","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.2174\/1381612053764887","volume":"11","author":"Z Wang","year":"2005","unstructured":"Wang Z. The role of COX-2 in oral cancer development, and chemoprevention\/ treatment of oral cancer by selective COX-2 inhibitors. Curr Pharm Des. 2005;11(14):1771\u20137. https:\/\/doi.org\/10.2174\/1381612053764887.","journal-title":"Curr Pharm Des"},{"issue":"4","key":"3395_CR110","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S0016-5085(96)70083-5","volume":"111","author":"CS Williams","year":"1996","unstructured":"Williams CS, Luongo C, Radhika A, Zhang T, Lamps LW, Nanney LB, Beauchamp RD, DuBois RN. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology. 1996;111(4):1134\u201340. https:\/\/doi.org\/10.1016\/S0016-5085(96)70083-5.","journal-title":"Gastroenterology"},{"issue":"6","key":"3395_CR111","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1136\/gutjnl-2011-300154","volume":"61","author":"BC Wong","year":"2012","unstructured":"Wong BC, Zhang L, Ma JL, Pan KF, Li JY, Shen L, Liu WD, Feng GS, Zhang XD, Li J, Lu AP, Xia HH, Lam S, You WC. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut. 2012;61(6):812\u20138. https:\/\/doi.org\/10.1136\/gutjnl-2011-300154.","journal-title":"Gut"},{"issue":"4","key":"3395_CR112","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.7150\/thno.82182","volume":"13","author":"Q Wu","year":"2023","unstructured":"Wu Q, Liu Z, Gao Z, Luo Y, Li F, Yang C, Wang T, Meng X, Chen H, Li J, Kong Y, Dong C, Sun S, Chen C. KLF5 inhibition potentiates anti-PD1 efficacy by enhancing CD8+ T-cell-dependent antitumor immunity. Theranostics. 2023;13(4):1381\u2013400. https:\/\/doi.org\/10.7150\/thno.82182.","journal-title":"Theranostics"},{"issue":"16","key":"3395_CR113","doi-asserted-by":"publisher","first-page":"e716","DOI":"10.5435\/JAAOS-D-18-00491","volume":"28","author":"R Wustrack","year":"2020","unstructured":"Wustrack R, Rao SS, Morris CD. Musculoskeletal effects of cancer and cancer treatment. J Am Acad Orthop Surg. 2020;28(16):e716\u201328. https:\/\/doi.org\/10.5435\/JAAOS-D-18-00491.","journal-title":"J Am Acad Orthop Surg"},{"key":"3395_CR114","doi-asserted-by":"publisher","unstructured":"Zhou XY, Xu CQ, Lai NH, Hu Y, Zhang EX, Wu WJ, Zeng JX, Liu B, Zhang XJ. Tianma-Chuanxiong synergically inhibit glioma by regulating the miR-101\/COX-2\/AKT signal. J Ethnopharmacol. 2026;358:120939. https:\/\/doi.org\/10.1016\/j.jep.2025.120939","DOI":"10.1016\/j.jep.2025.120939"},{"key":"3395_CR115","doi-asserted-by":"publisher","first-page":"110516","DOI":"10.1016\/j.abb.2025.110516","volume":"771","author":"L Yang","year":"2025","unstructured":"Yang L, Akanyibah FA, Yao D, Jin T, Mao F. The role of COX-2 and its use as a therapeutic target in IBD and related colorectal cancer. Arch Biochem Biophys. 2025a;771:110516. https:\/\/doi.org\/10.1016\/j.abb.2025.110516.","journal-title":"Arch Biochem Biophys"},{"issue":"5","key":"3395_CR116","doi-asserted-by":"publisher","first-page":"103779","DOI":"10.1016\/j.autrev.2025.103779","volume":"24","author":"P Yang","year":"2025","unstructured":"Yang P, Liu Q, Zhang H, Wu M, Zhao J, Shen G, Zhao Y. Risk relationship between six autoimmune diseases and malignancies: An umbrella review. Autoimmun Rev. 2025b;24(5):103779. https:\/\/doi.org\/10.1016\/j.autrev.2025.103779.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"3395_CR117","doi-asserted-by":"publisher","first-page":"dyae006","DOI":"10.1093\/ije\/dyae006","volume":"53","author":"TO Yang","year":"2024","unstructured":"Yang TO, Floud S, Reeves GK, Million Women Study Collaborators. Rheumatoid arthritis and cancer risk in the Million Women Study. Int J Epidemiol. 2024;53(2):dyae006. https:\/\/doi.org\/10.1093\/ije\/dyae006.","journal-title":"Int J Epidemiol"},{"key":"3395_CR118","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.biopha.2015.01.018","volume":"70","author":"Y Yang","year":"2015","unstructured":"Yang Y, Yan J, Huang Y, Xu H, Zhang Y, Hu R, Jiang J, Chen Z, Jiang H. The cancer pain related factors affected by celecoxib together with cetuximab in head and neck squamous cell carcinoma. Biomed Pharmacother. 2015;70:181\u20139. https:\/\/doi.org\/10.1016\/j.biopha.2015.01.018.","journal-title":"Biomed Pharmacother"},{"key":"3395_CR119","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.semcancer.2016.02.001","volume":"40\u201341","author":"NS Yarla","year":"2016","unstructured":"Yarla NS, Bishayee A, Sethi G, Reddanna P, Kalle AM, Dhananjaya BL, Dowluru KS, Chintala R, Duddukuri GR. Targeting arachidonic acid pathway by natural products for cancer prevention and therapy. Semin Cancer Biol. 2016;40\u201341:48\u201381. https:\/\/doi.org\/10.1016\/j.semcancer.2016.02.001.","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"3395_CR120","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/ddg.14649","volume":"20","author":"H Yen","year":"2022","unstructured":"Yen H, Yen H, Drucker AM, Han J, Li WQ, Li T, Qureshi A, Cho E. COX-2 inhibitors show no preventive effect in the development of skin cancer. J Dtsch Dermatol Ges. 2022;20(2):157\u201366. https:\/\/doi.org\/10.1111\/ddg.14649.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"3395_CR121","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/rheumatology\/keae294","volume":"64","author":"L Yu","year":"2025","unstructured":"Yu L, Yan Y, Liu W, Huang S, Sun L, Ruan S. Association of ankylosing spondylitis with the risk of cancer: a meta-analysis of cohort studies. Rheumatology (Oxford). 2025;64(2):440\u201354. https:\/\/doi.org\/10.1093\/rheumatology\/keae294.","journal-title":"Rheumatology (Oxford)"},{"key":"3395_CR122","doi-asserted-by":"publisher","first-page":"122695","DOI":"10.1016\/j.biomaterials.2024.122695","volume":"311","author":"P Zhang","year":"2024","unstructured":"Zhang P, Zhong D, Yu Y, Wang L, Li Y, Liang Y, Shi Y, Duan M, Li B, Niu H, Xu Y. Integration of STING activation and COX-2 inhibition via steric-hindrance effect tuned nanoreactors for cancer chemoimmunotherapy. Biomaterials. 2024;311:122695. https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122695.","journal-title":"Biomaterials"},{"issue":"15","key":"3395_CR123","doi-asserted-by":"publisher","first-page":"11570","DOI":"10.1021\/acs.jmedchem.1c00890","volume":"64","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Ghosh A, Connolly PJ, King P, Wilde T, Wang J, Dong Y, Li X, Liao D, Chen H, Tian G, Suarez J, Bonnette WG, Pande V, Diloreto KA, Shi Y, Patel S, Pietrak B, Szewczuk L, Sensenhauser C, Dallas S, Edwards JP, Bachman KE, Evans DC. Gut-restricted selective cyclooxygenase-2 (COX-2) inhibitors for chemoprevention of colorectal cancer. J Med Chem. 2021;64(15):11570\u201396. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00890.","journal-title":"J Med Chem"},{"issue":"3","key":"3395_CR124","doi-asserted-by":"publisher","first-page":"e0151939","DOI":"10.1371\/journal.pone.0151939","volume":"11","author":"YY Zhou","year":"2016","unstructured":"Zhou YY, Hu ZG, Zeng FJ, Han J. Clinical profile of cyclooxygenase-2 inhibitors in treating non-small cell lung cancer: a meta-analysis of nine randomized clinical trials. PLoS ONE. 2016;11(3):e0151939. https:\/\/doi.org\/10.1371\/journal.pone.0151939.","journal-title":"PLoS ONE"},{"issue":"1","key":"3395_CR125","doi-asserted-by":"publisher","first-page":"111167","DOI":"10.1016\/j.ejso.2025.111167","volume":"52","author":"Y Zhou","year":"2026","unstructured":"Zhou Y, Zhang B, Yang K, Wang Z, Li Q, Wang W, Chen D, Ma J, Zhou J. Development of a circulating tumor DNA methylation biomarker panel for hepatocellular carcinoma detection. Eur J Surg Oncol. 2026;52(1):111167. https:\/\/doi.org\/10.1016\/j.ejso.2025.111167.","journal-title":"Eur J Surg Oncol"},{"issue":"5","key":"3395_CR126","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/cac2.12283","volume":"42","author":"Z Zhou","year":"2022","unstructured":"Zhou Z, Liu H, Yang Y, Zhou J, Zhao L, Chen H, Fei Y, Zhang W, Li M, Zhao Y, Zeng X, Zhang F, Yang H, Zhang X. The five major autoimmune diseases increase the risk of cancer: epidemiological data from a large-scale cohort study in China. Cancer Commun (Lond). 2022;42(5):435\u201346. https:\/\/doi.org\/10.1002\/cac2.12283.","journal-title":"Cancer Commun (Lond)"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03395-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03395-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03395-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:41:42Z","timestamp":1792096902000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03395-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":126,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["3395"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03395-3","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"21 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"276"}}